Evidence has accumulated suggesting that HIV-infected patients are und
er chronic oxidative stress. Perturbations to the antioxidant defense
system, including changes in levels of ascorbic acid, tocopherols, car
otenoids, selenium, superoxide dismutase, and glutathione, have been o
bserved in various tissues of these patients. Elevated serum levels of
hydroperoxides and malondialdehyde also have been noted and are indic
ative of oxidative stress during HIV infection. Indications of oxidati
ve stress are observed in asymptomatic HIV-infected patients early in
the course of the disease. Oxidative stress may contribute to several
aspects of HIV disease pathogenesis, including viral replication, infl
ammatory response, decreased immune cell proliferation, loss of immune
function, apoptosis, chronic weight loss, and increased sensitivity t
o drug toxicities. Glutathione may play a role in these processes, and
thus, agents that replete glutathione may offer a promising treatment
for HIV-infected patients. Clinical studies are underway to evaluate
the efficacy of the glutathione-repleting agents, L-2-oxothiazolidine-
4-carboxylic acid (OTC) and N-acetylcysteine (NAG), in HIV-infected pa
tients.